Molecular Partners AG MOLN
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Molecular Partners AG (MOLN) is a healthcare company listed in the US with a market value of about $110M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -25%.
About Molecular Partners
Molecular Partners is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $21M in 2019 to $5M in 2024, a decline of about 23.6% a year. It was profitable in 1 of the last 7 years in our data.
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $5M | $8M | $205M | $11M | $11M | $21M |
| Net income | -$78M | -$60M | -$74M | $128M | -$70M | -$71M | -$38M |
| Free cash flow | -$66M | -$66M | -$71M | $127M | -$101M | -$35M | -$2M |
| EPS (diluted) | $-2.07 | $-1.59 | $-1.97 | $3.40 | $-1.86 | $-1.90 | $-1.00 |
| Net margin | — | -1087.4% | -880.7% | 62.2% | -653.9% | -671.7% | -178.0% |
| ROIC | -57.2% | -34.1% | -34.6% | 49.6% | -46.7% | -54.4% | -53.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Molecular Partners pay a dividend?
Not currently.
Is Molecular Partners a good stock to buy?
We do not give buy or sell advice. Molecular Partners scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.